At a glance
ClinicalIndex Comparison RecordN/ACompleted· 56 enrolled
Drug / intervention
Placebo +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Nicotinamide Mononucleotide (NMN) Supplementation on Organ System Biology
In Brief
A clinical study evaluating Placebo and Treatment for Glucose Metabolism Disorders. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlucose Metabolism Disorders
CountriesUnited States
CollaboratorsUnited States Department of Defense
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartOct 2020
Primary CompletionMar 2025
TodayJul 2026
First PostedSep 30, 2020
Enrollment StartOct 1, 2020
Primary CompletionMar 4, 2025
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 5.8 years ago
Interventions
Placeboother
Intervention will last at least 16 weeks in the form of two capsules.
Treatmentdietary
Intervention will last at least 16 weeks in the form of two or three NMN capsules (total of 300 or 450 mg/day).